The Quantellect read.As of Nov 19, 2026, 6 active firms cover Health Catalyst Inc: 0 rate it Buy or better, 6 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets range widely, $1.50 to $3.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $2.01 sits 56% above the current $1.29. The rating mix has stayed broadly stable, with Buy-side ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.00 next quarter toward $-0.02 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Neutral
Strong Buy00%
Buy00%
Neutral6100%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$2.01
+55.7% upside
Average target across 6 active firms as of Nov 19, 2026 vs $1.29 current
Highest Target$3.00
Average Target$2.01
Lowest Target$1.50
Detailed analyst forecasts for HCAT
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 0 of 6 active firms rate HCAT a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HCAT EPS & revenue forecast
EPS · NEXT QUARTER
$0.00
Range $-0.01 – $0.01 · 2 analysts · -100% YoY
Next period, 2 analysts expect Health Catalyst Inc to earn $0.00 a share (range $-0.01 – $0.01), versus $0.02 a year earlier. Full-year consensus is $-0.04, growing to $-0.02 the year after.
REVENUE · NEXT QUARTER
$49.0M
Range $46.2M – $51.0M · 2 analysts · -31% YoY
Revenue is expected to reach $49.0M (range $46.2M – $51.0M), -30.7% year-over-year. Full-year consensus is $247.9M, rising to $201.6M next year.
Top analysts covering Health Catalyst Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HCAT.
#1
Sarah James
Cantor Fitzgerald · Rank #159
Neutral
$3.00+132.6% to target
Overall win rate
37%
+ Follow
#2
Richard Close
Canaccord Genuity · Rank #249
Neutral
$1.80+39.5% to target
Overall win rate
37%
+ Follow
#3
Scott Schoenhaus
Keybanc · Rank #540
Buy
$4.00+210.1% to target
Overall win rate
30%
+ Follow
#4
Daniel Grosslight
Citigroup
Neutral
$2.00+55.0% to target
Coverage
—
+ Follow
#5
Stan Berenshteyn
Wells Fargo
Neutral
$1.50+16.3% to target
Coverage
—
+ Follow
HCAT stock forecast FAQ
What is HCAT's average 12-month price target?+
The 6 active firms with a live target average $2.01 for Health Catalyst Inc over the next 12 months, ranging from a $3.00 high to a $1.50 low, as of Nov 19, 2026.
Is HCAT stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 6 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 6 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for HCAT?+
The Street-high target is $3.00 (Cantor Fitzgerald), and the Street-low is $1.50 (Wells Fargo). The average of all 6 active-firm targets is $2.01.
How many active Wall Street firms cover HCAT?+
6 active firms have a recognized rating on Health Catalyst Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HCAT?+
Among analysts who currently cover HCAT, Sarah James of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #159). Their current call is Neutral with a $3.00 target.
What is Health Catalyst Inc's projected EPS for next quarter?+
The consensus estimate is $0.00 per share (range $-0.01 – $0.01) across 2 analysts. Full-year EPS is projected at $-0.04, rising to $-0.02 the following year.
How much revenue is Health Catalyst Inc expected to report next quarter?+
Consensus revenue is $49.0M (range $46.2M – $51.0M). Full-year revenue is projected at $247.9M, growing to $201.6M next year.
Have analysts been upgrading or downgrading HCAT lately?+
As of Nov 19, 2026, 0 of 6 active firms rate HCAT a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HCAT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.